Lupus

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tackey, E
Right arrow Articles by Illei, G G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tackey, E
Right arrow Articles by Illei, G G
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Lupus, Vol. 13, No. 5, 339-343 (2004)
DOI: 10.1191/0961203304lu1023oa

Rationale for interleukin-6 blockade in systemic lupus erythematosus

E Tackey

Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, USA

P E Lipsky

Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, USA

G G Illei

Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, USA, illeig{at}mail.nih.gov

Interleukin-6 (IL-6) is a pleiotropic cytokine with a wide range of biological activities that plays an important role in immune regulation and inflammation. Among other actions, it induces terminal differentiation of B lymphocytes into antibody-forming cells and the differentiation of T cells into effector cells. IL-6 also has multiple potent proinflammatory effects. An associationbetween IL-6 and lupus was demonstrated in murine models of SLE and blocking IL-6 improved lupus in all models tested. Data from several studies suggest that IL-6 plays a critical role in the B cell hyperactivity and immunopathology of human SLE, and may have a direct role in mediating tissue damage. Based on these data, we propose that blocking the effect of IL-6 in humans may improve lupus by interacting with the autoinflammatory process both systemically and locally.

Key Words: autoimmunity • biologic therapy • cytokines • experimental treatment


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
M. R. Gilbert, D. G. Carnathan, P. C. Cogswell, L. Lin, A. S. Baldwin Jr, and B. J. Vilen
Dendritic Cells from Lupus-Prone Mice Are Defective in Repressing Immunoglobulin Secretion
J. Immunol., April 15, 2007; 178(8): 4803 - 4810.
[Abstract] [Full Text] [PDF]


Home page
J. Gerontol. A Biol. Sci. Med. Sci.Home page
M. Maggio, J. M. Guralnik, D. L. Longo, and L. Ferrucci
Interleukin-6 in aging and chronic disease: a magnificent pathway.
J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2006; 61(6): 575 - 584.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
A Wozniacka, A Lesiak, J Narbutt, D P McCauliffe, and A Sysa-Jedrzejowska
Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients
Lupus, May 1, 2006; 15(5): 268 - 275.
[Abstract] [PDF]


Home page
BloodHome page
E. Savarese, O.-w. Chae, S. Trowitzsch, G. Weber, B. Kastner, S. Akira, H. Wagner, R. M. Schmid, S. Bauer, and A. Krug
U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7
Blood, April 15, 2006; 107(8): 3229 - 3234.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
S. V. Navarra
Immune therapy of lupus: what is on the horizon?
Nephrol. Dial. Transplant., March 1, 2006; 21(3): 579 - 581.
[Full Text] [PDF]


Home page
J. Immunol.Home page
B. Chen, S. Tsui, and T. J. Smith
IL-1{beta} Induces IL-6 Expression in Human Orbital Fibroblasts: Identification of an Anatomic-Site Specific Phenotypic Attribute Relevant to Thyroid-Associated Ophthalmopathy
J. Immunol., July 15, 2005; 175(2): 1310 - 1319.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
S Vasoo and G R. Hughes
Theory, targets and therapy in systemic lupus erythematosus
Lupus, March 1, 2005; 14(3): 181 - 188.
[Abstract] [PDF]